One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.